In a report released on March 24, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Eledon Pharmaceuticals in a report released on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will ...

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

A struggle that pits regional environmental activists against an airport expansion for private jets has national—and even ...

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its price objective dropped by Leerink Partners from $19.00 to $18.00 ...

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

CVS Health saw a notable shift as Tocqueville Asset Management slashed its stake in the company by over 50% in Q4. Other ...

Fintel reports that on March 24, 2025, Leerink Partners initiated coverage of Medpace Holdings (NasdaqGS:MEDP) with a Market ...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...

Hi. Good morning, everybody. We're ready for our next session at the [indiscernible]. Richard Francis, CEO of Teva. Thank you so much for joining us. I used to cover Teva a long time ago and have ...